Your browser doesn't support javascript.
loading
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ugarte-Gil, Manuel Francisco; Hanly, John; Urowitz, Murray; Gordon, Caroline; Bae, Sang-Cheol; Romero-Diaz, Juanita; Sanchez-Guerrero, Jorge; Bernatsky, Sasha; Clarke, Ann Elaine; Wallace, Daniel J; Isenberg, David Alan; Rahman, Anisur; Merrill, Joan T; Fortin, Paul R; Gladman, Dafna D; Bruce, Ian N; Petri, Michelle; Ginzler, Ellen M; Dooley, Mary Anne; Ramsey-Goldman, Rosalind; Manzi, Susan; Jönsen, Andreas; van Vollenhoven, Ronald F; Aranow, Cynthia; Mackay, Meggan; Ruiz-Irastorza, Guillermo; Lim, Sam; Inanc, Murat; Kalunian, Ken; Jacobsen, Søren; Peschken, Christine; Kamen, Diane L; Askanase, Anca; Pons-Estel, Bernardo A; Alarcón, Graciela S.
Afiliação
  • Ugarte-Gil MF; Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistemicas, Universidad Cientifica del Sur, Lima, Peru mugarte@cientifica.edu.pe.
  • Hanly J; Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
  • Urowitz M; Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
  • Gordon C; Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Bae SC; Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Romero-Diaz J; Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
  • Sanchez-Guerrero J; Hanyang University Institute for Rheumatology Research and Hanyang University Institute of Bioscience and Biotechnology, Seoul, South Korea.
  • Bernatsky S; Inmunología y Reumatología, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
  • Clarke AE; Inmunología y Reumatología, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
  • Wallace DJ; Sinai Health System and University Health Network, Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada.
  • Isenberg DA; Divisions of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Québec, Canada.
  • Rahman A; Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Merrill JT; Cedars Sinai/David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
  • Fortin PR; Medicine, University College London, London, UK.
  • Gladman DD; Medicine, University College London, London, UK.
  • Bruce IN; Department of Clinical Pathology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Petri M; Centre ARThrite, Rheumatology, CHU de Québec - Université Laval, Quebec, Quebec, Canada.
  • Ginzler EM; Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Dooley MA; Faculty of Biology Medicine and Health, Manchester Academic Health Sciences Center, University of Manchester, Manchester, UK.
  • Ramsey-Goldman R; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Manzi S; Department of Medicine, SUNY Downstate Medical Center, Brooklyn, New York, USA.
  • Jönsen A; Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, North Carolina, USA.
  • van Vollenhoven RF; Department of Medicine, Division of Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, Illinois, USA.
  • Aranow C; Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Mackay M; Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden.
  • Ruiz-Irastorza G; Department of Rheumatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Lim S; Northwell Health Manhasset, The Feinstein Institute for Medical Research, Manhasset, New York, USA.
  • Inanc M; Northwell Health Manhasset, The Feinstein Institute for Medical Research, Manhasset, New York, USA.
  • Kalunian K; Autoimmune Diseases Research Unit. BioCruces Bizkaia Health Research Institute, University of the Basque Country, Balakaldo, Spain.
  • Jacobsen S; School of Medicine, Division of Rheumatology, Emory University, Atlanta, Georgia, USA.
  • Peschken C; Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Capa, Istanbul, Turkey.
  • Kamen DL; School of Medicine, University of California San Diego, La Jolla, California, USA.
  • Askanase A; Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
  • Pons-Estel BA; Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Alarcón GS; Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA.
Ann Rheum Dis ; 81(11): 1541-1548, 2022 11.
Article em En | MEDLINE | ID: mdl-35944946
ABSTRACT

OBJECTIVE:

To determine the independent impact of different definitions of remission and low disease activity (LDA) on damage accrual.

METHODS:

Patients with ≥2 annual assessments from a longitudinal multinational inception lupus cohort were studied. Five mutually exclusive disease activity states were defined remission off-treatment clinical Systemic Lupus Erythematosus Disease Activity Index (cSLEDAI)-2K=0, without prednisone or immunosuppressants; remission on-treatment cSLEDAI-2K score=0, prednisone ≤5 mg/day and/or maintenance immunosuppressants; low disease activity Toronto cohort (LDA-TC) cSLEDAI-2K score of ≤2, without prednisone or immunosuppressants; modified lupus low disease activity (mLLDAS) Systemic Lupus Erythematosus Disease Activity Index-2K score of 4 with no activity in major organ/systems, no new disease activity, prednisone ≤7.5 mg/day and/or maintenance immunosuppressants; active all remaining visits. Only the most stringent definition was used per visit. Antimalarials were allowed in all. The proportion of time that patients were in a specific state at each visit since cohort entry was determined. Damage accrual was ascertained with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Univariable and multivariable generalised estimated equation negative binomial regression models were used. Time-dependent covariates were determined at the same annual visit as the disease activity state but the SDI at the subsequent visit.

RESULTS:

There were 1652 patients, 1464 (88.6%) female, mean age at diagnosis 34.2 (SD 13.4) years and mean follow-up time of 7.7 (SD 4.8) years. Being in remission off-treatment, remission on-treatment, LDA-TC and mLLDAS (per 25% increase) were each associated with a lower probability of damage accrual (remission off-treatment incidence rate ratio (IRR)=0.75, 95% CI 0.70 to 0.81; remission on-treatment IRR=0.68, 95% CI 0.62 to 0.75; LDA IRR=0.79, 95% CI 0.68 to 0.92; and mLLDAS IRR=0.76, 95% CI 0.65 to 0.89)).

CONCLUSIONS:

Remission on-treatment and off-treatment, LDA-TC and mLLDAS were associated with less damage accrual, even adjusting for possible confounders and effect modifiers.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 3_ND Problema de saúde: 3_malaria / 3_neglected_diseases Assunto principal: Lúpus Eritematoso Sistêmico / Antimaláricos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Peru

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 3_ND Problema de saúde: 3_malaria / 3_neglected_diseases Assunto principal: Lúpus Eritematoso Sistêmico / Antimaláricos Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Peru
...